Novo Nordisk Weighs UBT251 Triple Agonist Against Semaglutide In Next Trials [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk (CPSE:NOVO B) and United Laboratories report phase 2 data from China for UBT251 in type 2 diabetes. UBT251, a triple agonist, shows greater reductions in HbA1c and body weight than semaglutide in the trial. Novo Nordisk plans global phase 2 studies in diabetes and is already running a global trial focused on weight management. Novo Nordisk, listed as CPSE:NOVO B, is a major player in diabetes and obesity treatments, an area that has drawn strong interest from both patients and investors. The new UBT251 data adds another candidate to its pipeline alongside existing GLP 1 based therapies. As weight management drugs become a bigger focus across healthcare, this kind of multi target approach is drawing close attention. For investors following obesity and diabetes therapies, UBT251 adds another perspective on how Novo Nordisk might position future products. With global phase 2 diabetes studies planned and a weight management trial already underway, the company is movi
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Weak Share Performance [Yahoo! Finance]Yahoo! Finance
- Obesity drugmaker Kailera plans an IPO [Yahoo! Finance]Yahoo! Finance
- Mars CEO gets board role at GLP-1 supplier Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk (NVO) Shares Up Since Jim Cramer Said He Was A Buyer [Yahoo! Finance]Yahoo! Finance
- Stocks, sectors, and charts this strategist is watching [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/30/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- NVO's page on the SEC website